Skip to main content
. 2017 Jun 29;165(3):573–583. doi: 10.1007/s10549-017-4358-6

Fig. 2.

Fig. 2

DFS for patients with RS ≤ 11, 12–25, and > 25 overall (a), node-negative patients (b), for patients with pN1 disease (c), and for patients with pN2-3 disease (d)